Researchers have found a potential target for therapy in a kind of adult brain tumour that promises to pave the way for treatment of other type of cancers as well, says a study.
Glioblastomas are the most common form of brain tumour in adults -- and the most aggressive. Because of the way the tumours invasively infiltrate the brain, spreading like ivy, they cannot be removed fully by surgery. There is no cure, and few patients survive more than two to three years even with aggressive treatment.
The University of Virginia Cancer Center (UVA) researchers, however, have identified a potential target they believe is essential to the glioblastoma cells. This vital enzyme, they believe, regulates cancer cell survival, proliferation, and tumour formation. Inhibit the enzyme, their work suggests, and the cancer cell dies, reports Science Daily.
"This is an exciting new target in cancer," said UVA's Benjamin W. Purow, M. "It seems to have potential not just for brain tumours but for other cancers as well. We think it has activity on its own, but also in combination with other cancer therapies."
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
